Table 1.
Patients’ Baseline Characteristics
| Characteristic | Cohort 1 | Cohort 2 | Overall |
|---|---|---|---|
| Age, years | |||
| Median | 54 | 49 | 53 |
| Range | 21 – 75 | 20 – 68 | 20 – 75 |
| Sex, No. (%) | |||
| Male | 15 (68%) | 15 (65%) | 30 (67%) |
| Female | 7 (32%) | 8 (35%) | 15 (33%) |
| Total | 22 | 23 | 45 |
| WHO performance status, No. (%) | |||
| 0 | 16 (73%) | 8 (35%) | 24 (53%) |
| 1 | 6 (27%) | 15 (65%) | 21 (47%) |
| MGMT methylation status, No. (%†) | |||
| Methylated | 8 (42%) | 3 (16%) | 11 (29%) |
| Unmethylated | 11 (58%) | 16 (84%) | 27 (71%) |
| Unavailable | 3 | 4 | 7 |
| Lymphocyte count, x109/L | |||
| Median | 1.49* | 0.80* | 1.12 |
| Range | 0.88 – 2.50 | 0.35 – 1.91 | 0.35 – 2.50 |
| Concomitant steroid use, No. (%) | |||
| Yes | 16 (73%) | 17 (74%) | 43 (73%) |
| Entry concomitant steroid dose, mg | |||
| Median | 2.0 | 1.5 | 2.0 |
| Range | 0 – 4.0 | 0 – 4.0 | 0 – 4.0 |
Abbreviations: WHO, World Health Organization; MGMT, O6-Methylguanine DNA methyltransferase.
†
Percentages calculated excluding those patients whose MGMT methylation status was unavailable.
*
Significantly different lymphocyte counts between the two cohorts; p < 0.0001, two-tailed Man-Whitney test.